165 related articles for article (PubMed ID: 9228199)
1. Efflux studies allow further characterisation of the noradrenaline and 5-hydroxytryptamine transporters in rat lungs.
James KM; Bryan-Lluka LJ
Naunyn Schmiedebergs Arch Pharmacol; 1997 Jul; 356(1):126-33. PubMed ID: 9228199
[TBL] [Abstract][Full Text] [Related]
2. Conclusive evidence for distinct transporters for 5-hydroxytryptamine and noradrenaline in pulmonary endothelial cells of the rat.
Paczkowski NJ; Vuocolo HE; Bryan-Lluka LJ
Naunyn Schmiedebergs Arch Pharmacol; 1996 Mar; 353(4):423-30. PubMed ID: 8935709
[TBL] [Abstract][Full Text] [Related]
3. Evidence for uptake1-mediated efflux of catecholamines from pulmonary endothelial cells of perfused lungs of rats.
Westwood NN; Scarcella DL; Bryan-Lluka LJ
Naunyn Schmiedebergs Arch Pharmacol; 1996 Apr; 353(5):528-35. PubMed ID: 8740146
[TBL] [Abstract][Full Text] [Related]
4. Amezinium and debrisoquine are substrates of uptake1 and potent inhibitors of monoamine oxidase in perfused lungs of rats.
Bryan-Lluka LJ; Seers H; Sharpe I
Naunyn Schmiedebergs Arch Pharmacol; 1996 Apr; 353(5):536-44. PubMed ID: 8740147
[TBL] [Abstract][Full Text] [Related]
5. In vivo effects of the simultaneous blockade of serotonin and norepinephrine transporters on serotonergic function. Microdialysis studies.
Bel N; Artigas F
J Pharmacol Exp Ther; 1996 Sep; 278(3):1064-72. PubMed ID: 8819487
[TBL] [Abstract][Full Text] [Related]
6. Lanthanides inhibit the human noradrenaline, 5-hydroxytryptamine and dopamine transporters.
Bryan-Lluka LJ; Bönisch H
Naunyn Schmiedebergs Arch Pharmacol; 1997 Jun; 355(6):699-706. PubMed ID: 9205953
[TBL] [Abstract][Full Text] [Related]
7. Effects of norepinephrine and serotonin transporter inhibitors on hyperactivity induced by neonatal 6-hydroxydopamine lesioning in rats.
Davids E; Zhang K; Kula NS; Tarazi FI; Baldessarini RJ
J Pharmacol Exp Ther; 2002 Jun; 301(3):1097-102. PubMed ID: 12023542
[TBL] [Abstract][Full Text] [Related]
8. Distinct effects of imipramine on 5-hydroxytryptamine uptake mediated by the recombinant rat serotonin transporter SERT1.
Sur C; Betz H; Schloss P
J Neurochem; 1998 Jun; 70(6):2545-53. PubMed ID: 9603221
[TBL] [Abstract][Full Text] [Related]
9. Affinities of venlafaxine and various reuptake inhibitors for the serotonin and norepinephrine transporters.
Béïque JC; Lavoie N; de Montigny C; Debonnel G
Eur J Pharmacol; 1998 May; 349(1):129-32. PubMed ID: 9669506
[TBL] [Abstract][Full Text] [Related]
10. Characterization of carrier-mediated efflux in human embryonic kidney 293 cells stably expressing the rat serotonin transporter: a superfusion study.
Sitte HH; Scholze P; Schloss P; Pifl C; Singer EA
J Neurochem; 2000 Mar; 74(3):1317-24. PubMed ID: 10693966
[TBL] [Abstract][Full Text] [Related]
11. S33005, a novel ligand at both serotonin and norepinephrine transporters: I. Receptor binding, electrophysiological, and neurochemical profile in comparison with venlafaxine, reboxetine, citalopram, and clomipramine.
Millan MJ; Gobert A; Lejeune F; Newman-Tancredi A; Rivet JM; Auclair A; Peglion JL
J Pharmacol Exp Ther; 2001 Aug; 298(2):565-80. PubMed ID: 11454918
[TBL] [Abstract][Full Text] [Related]
12. [3H]substrate- and cell-specific effects of uptake inhibitors on human dopamine and serotonin transporter-mediated efflux.
Johnson RA; Eshleman AJ; Meyers T; Neve KA; Janowsky A
Synapse; 1998 Sep; 30(1):97-106. PubMed ID: 9704886
[TBL] [Abstract][Full Text] [Related]
13. Effect of long-term administration of duloxetine on the function of serotonin and noradrenaline terminals in the rat brain.
Rueter LE; Kasamo K; de Montigny C; Blier P
Naunyn Schmiedebergs Arch Pharmacol; 1998 Jun; 357(6):600-10. PubMed ID: 9686935
[TBL] [Abstract][Full Text] [Related]
14. Effects of chronic antidepressant treatments on 5-HT and NA transporters in rat brain: an autoradiographic study.
Hébert C; Habimana A; Elie R; Reader TA
Neurochem Int; 2001 Jan; 38(1):63-74. PubMed ID: 10913689
[TBL] [Abstract][Full Text] [Related]
15. Escitalopram, the S-(+)-enantiomer of citalopram, is a selective serotonin reuptake inhibitor with potent effects in animal models predictive of antidepressant and anxiolytic activities.
Sánchez C; Bergqvist PB; Brennum LT; Gupta S; Hogg S; Larsen A; Wiborg O
Psychopharmacology (Berl); 2003 Jun; 167(4):353-62. PubMed ID: 12719960
[TBL] [Abstract][Full Text] [Related]
16. Transporter-mediated release: a superfusion study on human embryonic kidney cells stably expressing the human serotonin transporter.
Scholze P; Zwach J; Kattinger A; Pifl C; Singer EA; Sitte HH
J Pharmacol Exp Ther; 2000 Jun; 293(3):870-8. PubMed ID: 10869387
[TBL] [Abstract][Full Text] [Related]
17. Molecular mechanism of citalopram and cocaine interactions with neurotransmitter transporters.
Ravna AW; Sylte I; Dahl SG
J Pharmacol Exp Ther; 2003 Oct; 307(1):34-41. PubMed ID: 12944499
[TBL] [Abstract][Full Text] [Related]
18. Increased noradrenaline efflux induced by local infusion of fluoxetine in the rat frontal cortex.
Hughes ZA; Stanford SC
Eur J Pharmacol; 1996 Dec; 317(1):83-90. PubMed ID: 8982723
[TBL] [Abstract][Full Text] [Related]
19. Reciprocal effects of combined administration of serotonin, noradrenaline and dopamine reuptake inhibitors on serotonin and dopamine levels in the rat prefrontal cortex: the role of 5-HT1A receptors.
Weikop P; Kehr J; Scheel-Krüger J
J Psychopharmacol; 2007 Nov; 21(8):795-804. PubMed ID: 17984160
[TBL] [Abstract][Full Text] [Related]
20. Syntheses and binding studies of new [(aryl)(aryloxy)methyl]piperidine derivatives and related compounds as potential antidepressant drugs with high affinity for serotonin (5-HT) and norepinephrine (NE) transporters.
Orjales A; Mosquera R; Toledo A; Pumar MC; García N; Cortizo L; Labeaga L; Innerárity A
J Med Chem; 2003 Dec; 46(25):5512-32. PubMed ID: 14640559
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]